Last update July 30, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
アンブリセンタン is Ambrisentan in Japanese.Is written in other languages:
アンブリセンタン belongs to these groups or families:
Main tradenames from several countries containing アンブリセンタン in its composition:
|Tmax||1.5 (1 - 2)||hours|
|T½||15 (13.6 – 16.5)||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a selective antagonist of the endothelin receptor (ARE) of the propanoic acid group. Indicated in the treatment of idiopathic pulmonary arterial hypertension or associated with connective tissue disease. Single daily dose oral administration.
At the date of the last update, there was no published data available on its excretion in human milk.
Its pharmacokinetic data (high percentage of protein binding and acid pKa) make it unlikely for it to pass into the mothers’ milk in a clinically significant amount.
It is a generally well-tolerated medication with infrequent or serious side effects. (Wei 2016, Frampton 2011)
Its use in Pediatrics is unauthorized.
Until more information is known about this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.